Geron stock tumbles after halting Phase 3 trial

What happened: Geron Corporation (NASDAQ:GERN) said it will discontinue its Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis after a Data Monitoring Committee recommendation. Key numbers: Shares fell 12% Wednesday. Why it matters: The DMC advised the trial was unlikely to meet its primary endpoint of overall survival. Geron said it remains committed to growing RYTELO demand in the U.S. and broadening access outside the U.S. Market: +0.0% today ($1.15), -12.9% YTD — as of 12:00 UTC

Geron Corporation (NASDAQ:GERN) said it will discontinue its Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis after a Data Monitoring Committee recommendation.

The DMC advised the trial was unlikely to meet its primary endpoint of overall survival. Geron said it remains committed to growing RYTELO demand in the U.S. and broadening access outside the U.S. Market: +0.0% today ($1.15), -12.9% YTD — as of 12:00 UTC